Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study

OBJECTIVE: The aim of this trial was to compare both the efficacy and the safety of a weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus cisplatin vs. gemcitabine plus cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). METHODS: A total of 84 participants received...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Shanshan, Yu, Hui, Wu, Xianghua, Luo, Zhiguo, Wang, Huijie, Sun, Si, Huang, Mingzhu, Jin, Jia, Tao, Zhonghua, Qiao, Jie, Feng, Yu, Wang, Jialei, Chang, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513743/
https://www.ncbi.nlm.nih.gov/pubmed/31156304
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.02.08

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513743/
https://www.ncbi.nlm.nih.gov/pubmed/31156304
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.02.08

Ejemplares similares